Michael R. Michaelides

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 813 citations · Full text

Lineage-specific Tumours, Medicine, Immune Checkpoint Inhibitor +8

Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a

Ramzi F. Sweis, Marina Pliushchev, Peter J. Brown et al. · ACS Medicinal Chemistry Letters · 2014 · 185 citations · Full text

Histone Modifications, Epigenetic Change, Genetics +18

Discovery of<i>N</i>-(4-(3-Amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor

Yujia Dai, Kresna Hartandi, Zhiqin Ji et al. · Journal of Medicinal Chemistry · 2007 · 180 citations · Full text

Compound 17P, Drug Target, Chemoprevention Strategy +20

Trifluoromethyl ketones as inhibitors of histone deacetylase

Robin R. Frey, Carol K. Wada, Robert B. Garland et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 147 citations · Full text

Histone Modifications, Chromatin, Medicinal Chemistry +10

The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity

Kenneth D. Bromberg, Taylor R. H. Mitchell, Anup K. Upadhyay et al. · Nature Chemical Biology · 2017 · 127 citations · Full text

Chromatin, Chromatin Remodeling, Epigenetic Change +10